Epithelial membrane protein 2 (EMP2) regulates hypoxia-induced angiogenesis in the adult retinal pigment epithelial cell lines.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 11 2022
Historique:
received: 28 03 2022
accepted: 18 10 2022
entrez: 13 11 2022
pubmed: 14 11 2022
medline: 16 11 2022
Statut: epublish

Résumé

Pathologic retinal neovascularization is a potentially blinding consequence seen in many common diseases including diabetic retinopathy, retinopathy of prematurity, and retinal vaso-occlusive diseases. This study investigates epithelial membrane protein 2 (EMP2) and its role as a possible modulator of angiogenesis in human retinal pigment epithelium (RPE) under hypoxic conditions. To study its effects, the RPE cell line ARPE-19 was genetically modified to either overexpress EMP2 or knock down its levels, and RNA sequencing and western blot analysis was performed to confirm the changes in expression at the RNA and protein level, respectively. Protein expression was evaluated under both normoxic conditions or hypoxic stress. Capillary tube formation assays with human umbilical vein endothelial cells (HUVEC) were used to evaluate functional responses. EMP2 expression was found to positively correlate with expression of pro-angiogenic factors HIF1α and VEGF at both mRNA and protein levels under hypoxic conditions. Mechanistically, EMP2 stabilized HIF1α expression through downregulation of von Hippel Lindau protein (pVHL). EMP2 mediated changes in ARPE-19 cells were also found to alter the secretion of a paracrine factor(s) in conditioned media that can regulate HUVEC migration and capillary tube formation in in vitro functional angiogenesis assays. This study identifies EMP2 as a potential mediator of angiogenesis in a human RPE cell line. EMP2 levels positively correlate with pro-angiogenic mediators HIF1α and VEGF, and mechanistically, EMP2 regulates HIF1α through downregulation of pVHL. This study supports further investigation of EMP2 as a promising novel target for therapeutic treatment of pathologic neovascularization in the retina.

Identifiants

pubmed: 36371458
doi: 10.1038/s41598-022-22696-x
pii: 10.1038/s41598-022-22696-x
pmc: PMC9653491
doi:

Substances chimiques

Vascular Endothelial Growth Factor A 0
Membrane Proteins 0
Retinal Pigments 0
EMP2 protein, human 0
Membrane Glycoproteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

19432

Subventions

Organisme : NEI NIH HHS
ID : R01 EY032561
Pays : United States
Organisme : NEI NIH HHS
ID : T32 EY007026
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

J Genet. 2009 Dec;88(4):495-515
pubmed: 20090210
Mol Cancer Ther. 2014 Apr;13(4):902-15
pubmed: 24448822
Br J Ophthalmol. 2021 Feb;105(2):216-221
pubmed: 32265201
Acta Ophthalmol. 2014 Dec;92(8):740-4
pubmed: 24739438
Exp Mol Med. 2004 Feb 29;36(1):1-12
pubmed: 15031665
J Biol Chem. 2014 May 16;289(20):13974-85
pubmed: 24644285
J Neurooncol. 2017 Aug;134(1):29-40
pubmed: 28597184
PLoS One. 2011;6(5):e19945
pubmed: 21637765
Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):648-52
pubmed: 19729615
Cell Death Differ. 2018 Dec;25(12):2071-2085
pubmed: 29666476
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1358-66
pubmed: 11350730
Transl Vis Sci Technol. 2016 Mar 11;5(2):10
pubmed: 26981332
Mol Pharmacol. 2006 Nov;70(5):1469-80
pubmed: 16887934
Drugs Context. 2018 Aug 13;7:212532
pubmed: 30181760
J Clin Neurosci. 2017 Oct;44:84-88
pubmed: 28720310
Int J Cancer. 2016 Mar 1;138(5):1058-66
pubmed: 25784597
Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2367-72
pubmed: 23439602
J Mol Med (Berl). 2013 Mar;91(3):311-21
pubmed: 23329331
Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):3
pubmed: 32031575
Cell. 2012 Feb 3;148(3):399-408
pubmed: 22304911
Exp Mol Pathol. 2003 Apr;74(2):106-12
pubmed: 12710941
Ophthalmol Retina. 2018 Dec;2(12):1179-1187
pubmed: 31047187
Exp Eye Res. 2003 Nov;77(5):593-9
pubmed: 14550401
Oncogene. 2017 Oct 19;36(42):5793-5807
pubmed: 28604744
Development. 2012 Jul;139(13):2340-50
pubmed: 22627278
Oncogene. 2013 Nov 14;32(46):5369-76
pubmed: 23334331
Bioinformatics. 2015 Sep 1;31(17):2912-4
pubmed: 25964631
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):245-254
pubmed: 30646013
Mol Cancer Ther. 2020 Aug;19(8):1682-1695
pubmed: 32451329
Curr Eye Res. 2011 Jun;36(6):546-52
pubmed: 21591864
BMC Ophthalmol. 2017 Jan 19;17(1):7
pubmed: 28103831

Auteurs

Michel Sun (M)

UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Nina Cherian (N)

UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Department of Pathology Lab Medicine, 4525 MacDonald Research Laboratories, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.

Lucia Liu (L)

Department of Pathology Lab Medicine, 4525 MacDonald Research Laboratories, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.

Ann M Chan (AM)

UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Brian Aguirre (B)

Department of Pathology Lab Medicine, 4525 MacDonald Research Laboratories, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.

Alison Chu (A)

Division of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Jason Strawbridge (J)

UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Esther S Kim (ES)

Division of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Meng-Chin Lin (MC)

Division of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Irena Tsui (I)

UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Lynn K Gordon (LK)

UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Madhuri Wadehra (M)

Department of Pathology Lab Medicine, 4525 MacDonald Research Laboratories, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA. mwadehra@mednet.ucla.edu.
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mwadehra@mednet.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH